Ryan Jacobs, MD, of the Atrium Health Levine cancer Institute in Charlotte, NC, provides an overview of the current treatment landscape for patients with chronic lymphocytic leukemia (CLL).

CLL is a rare blood cancer resulting in a build-up of lymphocytes in bone marrow, lymph nodes, and blood. As Dr. Jacobs notes, many advances have been made in the past few years to provide a variety of safe and effective options for patients with CLL. Among the targeted therapies, two Bruton tyrosine kinase inhibitors (BTKIs) are currently approved by the US Food and Drug Administration (FDA) – Ibrutinib and acalabrutinib. Another targeted therapy, venetoclax, targets BCL-2, a protein on CLL cells.

To learn more about CLL and other rare cancers, visit checkrare.com/diseases/cancers/

свернуть